No Covaxin stock in Delhi for any age group from Sunday: Atishi

"The Covishield stock for the 45-plus age group will last us 28 days," Atishi said.

Covaxin
Photo: Bloomberg
Press Trust of India New Delhi
2 min read Last Updated : Jun 04 2021 | 8:17 PM IST

AAP MLA Atishi said on Friday that it has been 12 days since the stock of Covaxin was over for the 18-44 age group and now Delhi will run out of vaccine supply for the 45-plus category by Sunday.

During her daily vaccination bulletin, Atishi said that the Delhi government had about 10,000 Covaxin shots till Friday morning.

"We have about six lakh doses for the 45-plus group, majority of which are Covishield. We think most of the stock of 10,000 Covaxin shots must be over by today evening. We are estimating that most of our centres that were administering Covaxin will be shut from tomorrow," she said.

"And by the day after tomorrow (Sunday), Covaxin will not be available at any centre," the AAP MLA added.

According to official data released by the Delhi government, it had 11,290 Covaxin shots, 5,87,760 Covishield shots available for the 45-plus age group till Friday morning.

The national capital administered 53,018 vaccine doses on Thursday, out of which the first dose was given to 37,747 people and 15,271 people received the second dose.

"The Covishield stock for the 45-plus age group will last us 28 days," Atishi said.

She added that those who were administered the first dose of Covaxin a month ago will need the second dose in two weeks.

"It's an urgent requirement to replenish the stock of Covaxin in Delhi. We request the Centre to supply the vaccine. We will require as many Covaxin doses as we had a month before so we can vaccinate those who need it for the second dose," Atishi said.

"Delhi can't do with five lakh vaccines, we need 50 lakh vaccines in the month of June," she added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 04 2021 | 8:11 PM IST

Next Story